![Three-day ODAC to review data from confirmatory trials of PD-1/PD-L1 drugs marketed under accelerated approval](https://cdn.cancerletter.com/media/2021/03/28073723/47-10-pazdur_4x3.jpg)
![Three-day ODAC to review data from confirmatory trials of PD-1/PD-L1 drugs marketed under accelerated approval](https://cdn.cancerletter.com/media/2021/03/28073723/47-10-pazdur_4x3.jpg)
Cover Story
FDA will hold a three-day meeting of the Oncologic Drugs Advisory Committee April 27-29 to consider five indications that received accelerated approvals, but that have not been shown to produce a clinical benefit in confirmatory trials.
In Brief
Clinical Roundup
![Clinical Roundup](https://cdn.cancerletter.com/media/2019/05/03161627/clinical_roundup.jpg)
![Clinical Roundup](https://cdn.cancerletter.com/media/2019/05/03161627/clinical_roundup.jpg)
Drugs & Targets
![Drugs & Targets](https://cdn.cancerletter.com/media/2019/05/03161633/targets2.jpg)
![Drugs & Targets](https://cdn.cancerletter.com/media/2019/05/03161633/targets2.jpg)
Trending Stories
- “All in Her Head” catalogs the history of medicine’s atrocities against women
- CM24 combination improves clinical outcomes in advanced metastatic PDAC in phase II study interim data
- Prominent GI oncologist Axel Grothey was forced out of Mayo Clinic for unethical sexual relationships with women he mentored
Three reprimands later, he retains leadership—and mentorship—positions - Chernobyl: a 35 year follow up on long-term health effects
- How a Georgetown med school student found her calling in surgery, law, and health equity
- The unKOOL, unfiltered history of menthol cigarettes